Global (n = 18) | Control patients (n = 9) | Toraymyxin treated patients (n = 9) | p value | |
---|---|---|---|---|
Age: years, mean (SD) | 67.5 (9.9) | 66 (10) | 69.1 (9.5) | 0.52 |
Male: n (%) | 6 (33.3) | 2 (22) | 4 (44) | 0.31 |
Apache II: mean (SD) | 20.67 (4.7) | 21.2 (5.3) | 20.1 (4.3) | 0.63 |
SOFA baseline mean (SD) | 11.3 (2.6) | 11.6 (2.9) | 11 (2.4) | 0.6 |
Sepsis focus n (%) | ||||
Peritonitis | 9 (50) | 4 (44) | 4 (44) | 0.4 |
Biliary tract | 4 (23) | 2 (22) | 3 (33) | |
Urinary tract | 5 (27) | 3 (33) | 2 (22) | |
RIFLE score (%) | ||||
Injury | 28 | 33 | 22 | 0.5 |
Failure | 72 | 64 | 78 | |
Vasoactive drugs (days), mean (SD) | 4.9 (3.8) | 4.5 (3.4) | 5.2 (4.3) | 0.72 |
IMV (days), mean (SD) | 9.4 (8.8) | 6.3 (8) | 12.4 (8.8) | 0.03 |
CRRT (days), mean (SD) | 6 (6) | 3.5 (1.9) | 8.5 (7.6) | 0.01 |
ICU LOS (days), mean (SD) | 19.8 (16.8) | 14.7 (16) | 24.9 (17) | 0.21 |
Hospital LOS (days), mean (SD) | 36 (31) | 32 (34) | 39.5 (29) | 0.64 |
ICU mortality (%) | 38.9 | 44.4 | 33.3 | 0.5 |
Hospital mortality (%) | 38.9 | 44.4 | 33.3 | 0.5 |